Sunshine Biopharma Sees 18% Revenue Growth in Q1 2025

Sunshine Biopharma ( (SBFM) ) has provided an update.

Sunshine Biopharma reported an 18% increase in revenues for the first quarter of 2025, reaching $8.9 million compared to the same period last year. The company appointed a new Chief Commercial Officer, launched six new generic drugs, and completed studies confirming the efficacy of its K1.1 mRNA Lipid Nanoparticle product for liver cancer. These developments reflect the company’s commitment to innovation and growth, positioning it for long-term success in the pharmaceutical industry.

The most recent analyst rating on (SBFM) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Sunshine Biopharma stock, see the SBFM Stock Forecast page.

Spark’s Take on SBFM Stock

According to Spark, TipRanks’ AI Analyst, SBFM is a Underperform.

Sunshine Biopharma’s stock score is primarily impacted by financial performance challenges, including significant yet unprofitable revenue growth and negative cash flows. Technical analysis indicators suggest bearish momentum, further influencing the negative outlook. Valuation concerns, such as a negative P/E ratio and lack of dividend yield, also weigh on the score. The company needs to address operational inefficiencies and improve profitability to enhance its stock performance.

To see Spark’s full report on SBFM stock, click here.

More about Sunshine Biopharma

Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines across various therapeutic areas, including oncology and antivirals. The company markets 70 generic prescription drugs in Canada and plans to launch 13 additional drugs in 2025, including NIOPEG®, a biosimilar of NEULASTA®. Sunshine Biopharma is also involved in proprietary drug development, focusing on an mRNA-Lipid Nanoparticle for liver cancer and a small molecule for treating SARS Coronavirus infections.

Average Trading Volume: 1,476,904

Technical Sentiment Signal: Strong Sell

Current Market Cap: $6.79M

For a thorough assessment of SBFM stock, go to TipRanks’ Stock Analysis page.